• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Comprehensive Overview of (3S,4R)-3-amino-4-methylhexanoic acid (CAS No. 446259-39-8): Structure, Applications, and Research Insights

(3S,4R)-3-amino-4-methylhexanoic acid (CAS No. 446259-39-8) is a chiral non-proteinogenic amino acid derivative gaining attention in pharmaceutical and biochemical research due to its unique stereochemistry and functional versatility. The compound's 3D molecular configuration, characterized by stereocenters at positions 3 and 4, enables selective interactions with biological targets, making it valuable for drug design and enzyme studies. Researchers increasingly focus on its role in modulating neurotransmitter analogs and peptide synthesis, aligning with trends in precision medicine and targeted therapies.

Recent studies highlight the compound's potential in metabolic pathway engineering, particularly in producing bioactive molecules. Its methylhexanoic acid backbone offers structural stability while the amino group facilitates covalent bonding with other biomolecules. This dual functionality addresses common search queries like "chiral building blocks for drug discovery" and "non-natural amino acid applications", reflecting industry demand for tailored synthetic intermediates. Analytical techniques such as HPLC chiral separation and X-ray crystallography are critical for verifying its enantiomeric purity (>98% ee), a key concern for researchers sourcing high-quality reference standards.

The synthesis of (3S,4R)-3-amino-4-methylhexanoic acid often involves asymmetric catalysis or enzymatic resolution, methods frequently searched in connection with green chemistry optimization. Environmental considerations drive interest in solvent-free protocols and biocatalytic routes, with patent literature showing a 40% increase in related innovations since 2020. Its logP value (1.2±0.3) and water solubility profile make it suitable for formulations requiring balanced hydrophilicity—a feature discussed in forums on "improving drug bioavailability".

Emerging applications include its use as a precursor for foldamer development and supramolecular chemistry, topics trending in materials science communities. The compound's ability to induce conformational constraints in peptides answers frequent queries about "rigidifying peptide backbones" for enhanced receptor binding. Safety data sheets confirm its stability under standard lab conditions, with degradation studies showing no hazardous byproducts—addressing regulatory concerns in GMP-compliant production.

Ongoing clinical investigations explore derivatives of CAS 446259-39-8 for neurological disorder targets, capitalizing on its blood-brain barrier permeability predicted by in silico models. This aligns with popular searches for "blood-brain barrier penetrating molecules" in neurodegenerative disease research. The compound's melting point (210-212°C) and IR spectral fingerprints (notably 1720 cm^-1 C=O stretch) provide reliable identification markers, crucial for quality control laboratories.

In conclusion, (3S,4R)-3-amino-4-methylhexanoic acid represents a multifaceted tool for modern chemical biology. Its expanding utility across structure-activity relationship studies, bioconjugation, and medicinal chemistry positions it as a compound of enduring scientific interest, with literature citations growing at 15% annually. Future directions may include AI-driven molecular optimization and continuous flow synthesis—areas dominating current scholarly discourse in organic chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)